Skip to content
← All interventions
Longevity compound

Resveratrol

Automated longevity evidence pipeline intervention.

Where the science stands

This page summarizes the current human evidence captured in the Longevity Compass database. Result interpretation is conservative and unresolved outcomes remain unknown.

Evidence depth 86 / 100

Research path

From biological idea to human evidence

These stages show different kinds of evidence for Resveratrol. Moving through them does not mean an intervention is proven to slow aging.

  1. 1

    Biological idea

    Reviewing animal and laboratory research…

  2. 2

    Human testing

    11 direct aging trial links and 29 related trial links tracked. A trial count describes research activity, not benefit.

  3. 3

    What results show

    0 beneficial, 0 neutral and 0 harmful result links interpreted; 42 remain unresolved.

  4. 4

    Still unanswered

    Whether these findings translate into meaningful, lasting healthy-aging benefits in people remains unproven. Longer follow-up and clearer safety and clinical outcomes are needed.

How AgeBeacon evaluates evidence →

Beyond human trials

The bigger longevity story

Loading animal and laboratory evidence…

Animal and cell studies help explain biological plausibility and identify promising directions. They are shown separately and do not increase the human evidence-depth score.

Signals we're watching

What human studies are measuring

Physical function

6 result(s) are linked, but direction remains unknown.

Muscle

8 result(s) are linked, but direction remains unknown.

Metabolic health

5 result(s) are linked, but direction remains unknown.

Cardiovascular

3 result(s) are linked, but direction remains unknown.

Cognition

2 result(s) are linked, but direction remains unknown.

Research depth

Human evidence picture

Evidence depth describes how much relevant human research exists; it is not an efficacy score. Unknown results are not treated as neutral.

11
Direct aging trials
29
Indirect relevant trials
75
Publications linked
15
Results publications

Interpreted results

Beneficial
0
Neutral
0
Harmful
0
Unknown / unresolved
42

Population relevance

Healthy / aging
6
Disease-specific
9

Safety evidence

1

Trials currently identified with safety-result data.

Go to the source

Studies & publications

Inspect the original evidence behind this profile. Links open the trial registry, PubMed or the publication DOI.

Biological Effects in Consumers of Resveratrol-enriched WineNCT05981053OBSERVATIONAL · 30 participants · COMPLETEDVIAging Deceleration Trial Using Metformin, Dasatinib, Rapamycin and Nutritional SupplementsNCT04994561INTERVENTIONAL · PHASE1 · WITHDRAWNAnti-age Dietary Supplements in Healthy Older Adults: the proBNPage Reduction TrialNCT05500742INTERVENTIONAL · NA · 120 participants · UNKNOWNResveratrol and Exercise to Treat Functional Limitations in Late LifeNCT02523274INTERVENTIONAL · PHASE2 · 60 participants · COMPLETEDHealthy Aging Through Functional FoodNCT02095873INTERVENTIONAL · PHASE1/PHASE2 · 32 participants · COMPLETEDEffects of Resveratrol in Patients With Type 2 DiabetesNCT01677611INTERVENTIONAL · PHASE1 · 10 participants · COMPLETEDInfluence of Caloric Restriction and Resveratrol in the Sirtuin System in Women and Men Aged 55 to 65 YearsNCT01668836INTERVENTIONAL · NA · 48 participants · COMPLETEDResveratrol to Enhance Vitality and Vigor in EldersNCT02123121INTERVENTIONAL · PHASE2 · 60 participants · COMPLETEDFood Supplement for LongevityNCT07659834INTERVENTIONAL · NA · 18 participants · ACTIVE_NOT_RECRUITINGStrength Training and ResveratrolNCT06585865INTERVENTIONAL · NA · 36 participants · RECRUITINGResveratrol for Improved Performance in the ElderlyNCT01126229INTERVENTIONAL · PHASE1 · 32 participants · COMPLETEDResveratrol In Chronic Obstructive Pulmonary Disease (COPD) Patients (CARMENS-trial)NCT02245932INTERVENTIONAL · NA · 23 participants · COMPLETEDDerella CC, Thomas J, Harris RA. Women Have Greater Endothelin-B Receptor Function and Lower Mitochondrial Capacity Compared to Men With Type 1 Diabetes. J Clin Endocrinol Metab. 2023 Sep 18;108(10):2561-2568. doi: 10.1210/clinem/dgad189.PMID 37009678Results publicationde Ligt M, Bruls YMH, Hansen J, Habets MF, Havekes B, Nascimento EBM, Moonen-Kornips E, Schaart G, Schrauwen-Hinderling VB, van Marken Lichtenbelt W, Schrauwen P. Resveratrol improves ex vivo mitochondrial function but does not affect insulin sensitivity or brown adipose tissue in first degree relatives of patients with type 2 diabetes. Mol Metab. 2018 Jun;12:39-47. doi: 10.1016/j.molmet.2018.04.004. Epub 2018 Apr 18.PMID 29706321Results publicationKnop FK, Konings E, Timmers S, Schrauwen P, Holst JJ, Blaak EE. Thirty days of resveratrol supplementation does not affect postprandial incretin hormone responses, but suppresses postprandial glucagon in obese subjects. Diabet Med. 2013 Oct;30(10):1214-8. doi: 10.1111/dme.12231. Epub 2013 Jun 7.PMID 23663119Results publicationMuscari A, Forti P, Brizi M, Magalotti D, Capelli E, Poti S, Piro F, Pandolfi P, Perlangeli V, Ramazzotti E, Barbara G; PBAR Study Group. Can We Slow Down Biological Age Progression? Study Protocol for the proBNPage Reduction (PBAR) Randomized, Double-Blind, Placebo-Controlled Trial (Effects of 4 "Anti-Aging" Food Supplements in Healthy Older Adults). Clin Interv Aging. 2023 Oct 27;18:1813-1825. doi: 10.2147/CIA.S422371. eCollection 2023.PMID 37915546Results publicationAnton SD, Embry C, Marsiske M, Lu X, Doss H, Leeuwenburgh C, Manini TM. Safety and metabolic outcomes of resveratrol supplementation in older adults: results of a twelve-week, placebo-controlled pilot study. Exp Gerontol. 2014 Sep;57:181-7. doi: 10.1016/j.exger.2014.05.015. Epub 2014 May 24.PMID 24866496Results publicationMost J, Goossens GH, Reijnders D, Canfora EE, Penders J, Blaak EE. Gut microbiota composition strongly correlates to peripheral insulin sensitivity in obese men but not in women. Benef Microbes. 2017 Aug 24;8(4):557-562. doi: 10.3920/BM2016.0189. Epub 2017 Jun 16.PMID 28618864Results publicationJardon KM, Goossens GH, Most J, Galazzo G, Venema K, Penders J, Blaak EE. Examination of sex-specific interactions between gut microbiota and host metabolism after 12-week combined polyphenol supplementation in individuals with overweight or obesity. Gut Microbes. 2024 Jan-Dec;16(1):2392875. doi: 10.1080/19490976.2024.2392875. Epub 2024 Aug 25.PMID 39182247Results publicationFazelzadeh P, Hoefsloot HCJ, Hankemeier T, Most J, Kersten S, Blaak EE, Boekschoten M, van Duynhoven J. Global testing of shifts in metabolic phenotype. Metabolomics. 2018 Oct 4;14(10):139. doi: 10.1007/s11306-018-1435-8.PMID 30830386Results publicationBeijers RJ, Gosker HR, Sanders KJ, de Theije C, Kelders M, Clarke G, Cryan JF, van den Borst B, Schols AM. Resveratrol and metabolic health in COPD: A proof-of-concept randomized controlled trial. Clin Nutr. 2020 Oct;39(10):2989-2997. doi: 10.1016/j.clnu.2020.01.002. Epub 2020 Jan 13.PMID 31996311Results publicationMost J, Timmers S, Warnke I, Jocken JW, van Boekschoten M, de Groot P, Bendik I, Schrauwen P, Goossens GH, Blaak EE. Combined epigallocatechin-3-gallate and resveratrol supplementation for 12 wk increases mitochondrial capacity and fat oxidation, but not insulin sensitivity, in obese humans: a randomized controlled trial. Am J Clin Nutr. 2016 Jul;104(1):215-27. doi: 10.3945/ajcn.115.122937. Epub 2016 May 18.PMID 27194304Results publicationZhu CW, Grossman H, Neugroschl J, Parker S, Burden A, Luo X, Sano M. A randomized, double-blind, placebo-controlled trial of resveratrol with glucose and malate (RGM) to slow the progression of Alzheimer's disease: A pilot study. Alzheimers Dement (N Y). 2018 Nov 9;4:609-616. doi: 10.1016/j.trci.2018.09.009. eCollection 2018.PMID 30480082Results publicationJimenez-Maggiora GA, Donohue MC, Rafii MS, Raman R, Aisen PS. Artificial intelligence-enabled safety monitoring in Alzheimer's disease clinical trials. J Prev Alzheimers Dis. 2025 Jan;12(1):100002. doi: 10.1016/j.tjpad.2024.100002. Epub 2025 Jan 1.PMID 39800465Results publication

The big unanswered question

Can promising biology translate into meaningful healthy-aging benefits?

That is the standard this evidence profile is tracking. New trials and results can strengthen, weaken or change the picture over time.

Confidence: moderateScore model: v0.5-curated-ruleUpdated: 2026-09-21Source: live evidence database